September 2019, Volume :119 Number 9 , page 10 - 10 [Free]
Join NursingCenter to get uninterrupted access to this Article
In the September 2018 Drug Watch, tofacitinib (Xeljanz) was incorrectly identified as a biologic; in fact, it is a Janus kinase inhibitor.
Aschenbrenner DS First oral drug for moderate-to-severe ulcerative colitis Am J Nurs 2018 118 9 22-3
Join NursingCenter on Social Media to find out the latest news and special offers
© 2024 Wolters Kluwer Health, Inc. and/or its subsidiaries. All rights reserved. – Terms & Conditions – Privacy Policy – Disclaimer – Your California Privacy Choices -- v09.02.00